Yahoo Finance • 15 hours ago
Quoin Pharmaceuticals (QNRX) shares soared 126% amid heavy trading intraday after the company said F PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 19 hours ago
ASHBURN, Va., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has... Full story
Yahoo Finance • 30 days ago
In trading on Tuesday, shares of MSCI Inc (Symbol: MSCI) crossed above their 200 day moving average of $513.38, changing hands as high as $520.93 per share. MSCI Inc shares are currently trading up about 3.3% on the day. The chart below... Full story
Yahoo Finance • last month
ASHBURN, Va., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the releas... Full story
Yahoo Finance • 2 months ago
* Quoin Pharmaceuticals (NASDAQ:QNRX [https://seekingalpha.com/symbol/QNRX]) on Monday announced the appointment of Sally Lawlor as its new Chief Financial Officer as the company advances its lead product candidate, QRX003, through pivot... Full story
Yahoo Finance • 2 months ago
ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appoint... Full story
Yahoo Finance • 2 months ago
Investing.com -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) stock rose 2.4% following the company’s update on its development product portfolio, highlighting progress in its lead product for Netherton Syndrome and other rare skin disease tre... Full story
Yahoo Finance • 2 months ago
Lead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., Europe, and the Middle East. QRX003 Peeling Skin Syndrome Clinical Program Continues Following Positive Initial Data... Full story
Yahoo Finance • 3 months ago
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX), a micro-cap pharmaceutical company with a market capitalization of $5.22 million, announced Monday that Chief Financial Officer Gordon Dunn will be leaving the company following a mutual agreement... Full story
Yahoo Finance • 4 months ago
ASHBURN, Va., June 26, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release... Full story
Yahoo Finance • 5 months ago
Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects.Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. A... Full story
Yahoo Finance • 5 months ago
Clear Improvement in Patient’s Skin Appearance Observed in Study after 12 weeks Compared to BaselineKey endpoints including Investigator’s Global Assessment (IGA), Modified Ichthyosis Area Severity (M-IASI) and Children’s Dermatology Life... Full story
Yahoo Finance • 6 months ago
Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company’s NETHERTON... Full story
Yahoo Finance • 6 months ago
Continued Clear Visual Evidence of Almost Completely Healed Skin After 6 weeks TreatmentHigh Durability of Treatment Effect of QRX003 with Continuous Daily Dosing Patient Continues Not to Require Previously Necessary MedicationsWith Patien... Full story
Yahoo Finance • 7 months ago
Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic DermatitisThird Quoin Patent Application for Netherton Syndrome If Granted Company Would have Patent Protection for QRX003 for... Full story
Yahoo Finance • 7 months ago
Groundbreaking data from first whole body application of QRX003 underscores potential efficacyTransformational improvement in disease state after just 2 weeks of treatment Clear visual evidence of skin healing observedImprovement has elimi... Full story
Yahoo Finance • 7 months ago
ASHBURN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the launch... Full story
Yahoo Finance • 8 months ago
Multi-pronged media campaign to raise awareness about the disease and its impact on patients, family members and caregivers.Interactive, stand-alone NETHERTON NOW website launched.Quoin’s QRX003 product is on track to obtain the first regu... Full story
Yahoo Finance • 2 years ago
Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study Positive benefits were observed across a number of clinical endpoints including pruritus, Investigator ski... Full story
Yahoo Finance • 2 years ago
ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company... Full story